Xilio Therapeutics Inc (XLO) — Titan Protect Analysis

XLO

Xilio Therapeutics Inc

Healthcare · ·

$7.70

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$54M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-14.14

Based on estimated future earnings — lower means cheaper

Rev Growth

+331.7%

Year-over-year revenue change

Profit Margin

-58.5%

How much profit the company keeps from each dollar of revenue

ROE

-75.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+160% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Xilio Therapeutics Inc

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA

https://xiliotx.com

Country: United States Employees: 76 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.296

Positive but modest risk-adjusted returns

Kelly Fraction

0.0005

Marginal edge — very small allocation suggested

Calmar Ratio

-0.364

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-23.8%

Historical annualised return based on price data

Max Drawdown

-65.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

233

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$12.74

40% below the year high

52W Low

$6.47

19% above the year low

Avg Volume

48,191

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.28

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

9.15

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-111.6%

Profit from core operations before interest and tax

Free Cash Flow

$-23,708,876

Negative — the business is spending more than it generates

Revenue (TTM)

$53M

Total revenue over the last 12 months

Net Income

$-31,300,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$20.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go